Skip to main content
Livermore
Livermore
US stocksTW
ZHEN

Johnson & Johnson

SEC CIK
0000200406
Latest filing
Oct 26, 2026

The latest 13F from Johnson & Johnson covers Q3 2026 (filed Oct 26, 2026): 15 long positions worth $761.7M. The top 10 holdings make up 98.8% of the portfolio, and the largest is Protagonist Therapeutics, Inc (PTGX) at 45.3%. Livermore has 24 filings on Form 13F from this institution, going back to Q3 2021.

What changed in Q3 2026

Full comparison

Share counts compared with Q2 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

New
0
Added
1
Est. +$13.3M
Reduced
0
Sold out
0

Top 5 holdings

Share of this quarter's portfolio value

  1. PTGXProtagonist Therapeutics, Inc
    45.3%$345.1MHistory
  2. NBTXNanobiotix S.A.
    23.0%$175.2MHistory
  3. MGTXMeiraGTx Holdings plc
    9.6%$73.1MHistory
  4. RAPPRapport Therapeutics, Inc.
    7.9%$60.0MHistory
  5. CTNMContineum Therapeutics, Inc.
    3.5%$26.6MHistory

Share of portfolio

Top 5 holdings and the other 10 positions, by share of portfolio value

  1. PTGX45.3%
  2. NBTX23.0%
  3. MGTX9.6%
  4. RAPP7.9%
  5. CTNM3.5%
  6. Other 10 positions10.7%

Biggest buys

New and added positions, by estimated amount bought

  1. CBRSCerebras Systems Inc.
    +$13.3MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. CBRSCerebras Systems Inc.
    +1.52 pp1.5% → 3.0%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

None this quarter.

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

None this quarter.

Metrics

13F metrics for Q3 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$761.7M
−$37.0M (−4.6%) vs. prior quarter
Positions
15
0 vs. prior quarter
Top 10 concentration
98.8%
Top 10 as share of value
Turnover
0.0%
Q3 2026, one quarter
Average holding period
17.3 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q3 2021), so positions held before then are understated.

13F filings by quarter

21 quarters, going back to Q3 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $4.41B (Q1 2024)

Q3 2021: $1.14BQ4 2021: $878.4MQ1 2022: $529.0MQ2 2022: $391.5MQ3 2022: $339.8MQ4 2022: $343.7MQ1 2023: $307.4MQ2 2023: $322.1MQ3 2023: $271.5MQ4 2023: $4.39BQ1 2024: $4.41BQ2 2024: $400.7MQ3 2024: $427.3MQ4 2024: $386.1MQ1 2025: $341.9MQ2 2025: $334.1MQ3 2025: $503.9MQ4 2025: $555.0MQ1 2026: $652.4MQ2 2026: $798.7MQ3 2026: $761.7M
Q3 2021Q3 2026
13F filings of Johnson & Johnson by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q3 2026Oct 26, 202615$761.7MPTGXNBTXMGTXvs. Q2 2026SEC
Q2 2026Aug 6, 202615$798.7MPTGXNBTXMGTXvs. Q1 2026SEC
Q1 2026May 13, 202616$652.4MPTGXNBTXMGTXvs. Q4 2025SEC
Q4 2025Mar 18, 2026Amended17$555.0MPTGXNBTXRAPPvs. Q3 2025SEC
Q3 2025Mar 18, 2026Amended20$503.9MPTGXNBTXMGTXvs. Q2 2025SEC
Q2 2025Jul 22, 202520$334.1MPTGXMGTXRAPPvs. Q1 2025SEC
Q1 2025May 7, 202520$341.9MPTGXCVRXMGTXvs. Q4 2024SEC
Q4 2024Feb 13, 202520$386.1MPTGXCVRXRAPPvs. Q3 2024SEC
Q3 2024Nov 13, 202420$427.3MPTGXRAPPLEGNvs. Q2 2024SEC
Q2 2024Aug 9, 202420$400.7MPTGXRAPPCVRXvs. Q1 2024SEC
Q1 2024May 10, 202422$4.41BKVUEFUSNCVRXvs. Q4 2023SEC
Q4 2023Feb 14, 202423$4.39BKVUECVRXPTGXvs. Q3 2023SEC
Q3 2023Nov 9, 202324$271.5MLEGNCVRXPTGXvs. Q2 2023SEC
Q2 2023Aug 2, 202322$322.1MPTGXLEGNCVRXvs. Q1 2023SEC
Q1 2023May 11, 202323$307.4MLEGNPTGXMGTXvs. Q4 2022SEC
Q4 2022Feb 9, 202322$343.7MLEGNCVRXMGTXvs. Q3 2022SEC
Q3 2022Nov 10, 202222$339.8MFATELEGNPRCTvs. Q2 2022SEC
Q2 2022Aug 10, 202222$391.5MLEGNFATEARWRvs. Q1 2022SEC
Q1 2022May 9, 202222$529.0MFATELEGNPTGXvs. Q4 2021SEC
Q4 2021Feb 14, 202224$878.4MARWRFATEPTGXvs. Q3 2021SEC
Q3 2021Nov 16, 2021Amended25$1.14BILMNARWRFATE–SEC

13D and 13G filings

Companies where Johnson & Johnson reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

1 company, largest stake first.

Companies where Johnson & Johnson owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
CVRXCVRx, Inc.13G/A15.40%4.02M shares–Feb 7, 20224 filingsJan 12, 2026SEC

Latest filings

21 filings on file made by Johnson & Johnson or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Johnson & Johnson
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
CTNMContineum Therapeutics, Inc.Nov 6, 202610:20 AM ETJohnson & Johnson Innovation - JJDC, Inc.and 1 other13G/A5.60%1.98M shares–Nov 3, 2026SEC
TRXBTRex Bio, Inc.Oct 15, 20261:21 PM ETJohnson & Johnson Innovation - JJDC, Inc.and 1 other13G5.30%1.48M sharesNewOct 13, 2026SEC
RLYBRallybio CorpApr 13, 202611:15 AM ETJohnson & Johnsonand 1 other13G/A2.90%152.9K shares–Below 5%Mar 31, 2026SEC
CVRXCVRx, Inc.Jan 12, 20267:51 PM ETJohnson & Johnsonand 1 other13G/A15.40%4.02M shares–Dec 31, 2025SEC
RAPPRapport Therapeutics, Inc.Oct 22, 20255:09 PM ETJohnson & Johnsonand 1 other13G/A4.90%1.78M shares–Below 5%Sep 30, 2025SEC
CVRXCVRx, Inc.Nov 1, 2024Johnson & Johnson13G/AOld format–––SEC
MGTXMeiraGTx Holdings plcOct 18, 20244:47 PM ETJohnson & Johnson13G/AOld format–––SEC
RAPPRapport Therapeutics, Inc.Oct 18, 2024Johnson & Johnson13GOld format–New–SEC
RLYBRallybio CorpJul 30, 2024Johnson & Johnson13GOld format–New–SEC
KVUEKenvue Inc.May 20, 2024Johnson & Johnson13G/AOld format–––SEC
CTNMContineum Therapeutics, Inc.Apr 10, 20245:12 PM ETJohnson & Johnson13GOld format–New–SEC
HLSQTessera Defense & Homeland Security Inc.Feb 2, 20245:07 PM ETJohnson & Johnson13G/AOld format–––SEC
NBTXNanobiotix S.A.Feb 2, 20244:32 PM ETJohnson & Johnson13G/AOld format–––SEC
CVRXCVRx, Inc.Feb 2, 2024Johnson & Johnson13G/AOld format–––SEC
KVUEKenvue Inc.Jan 24, 2024Johnson & Johnson13GOld format–New–SEC
FUSNFusion Pharmaceuticals Inc.Jan 27, 202311:12 AM ETJohnson & Johnson13G/AOld format–––SEC
PTGXProtagonist Therapeutics, IncJan 11, 20231:00 PM ETJohnson & Johnson13G/AOld format–––SEC
MGTXMeiraGTx Holdings plcNov 14, 20222:40 PM ETJohnson & Johnson13G/AOld format–––SEC
CVRXCVRx, Inc.Feb 7, 2022Johnson & Johnson13GOld format–New–SEC
PHASPhaseBio Pharmaceuticals IncFeb 1, 20222:42 PM ETJohnson & Johnson13G/AOld format–––SEC